Number: GOG 131H Principal Investigator: Mutch, David
Title: A Phase II Evaluation of Ixabepilone In The Treatment of Recurrent Or Persistent Leiomyosarcoma Of The Uterus
Phase: II Disease Site: Corpus Uteri
Participating Site(s):
Contact: 800-600-3606 or

The purpose of this study is to find out if the study drug, Ixabepilone, works in treating your type of cancer and to find out what side effects are caused by treatment with this drug.

The drug ixabepilone has been approved by the FDA (Food and Drug Administration) for use in patients with breast cancer, but is considered experimental for your type of cancer. Ixabepilone is a drug called an epothilone. Epothilones are similar to paclitaxel (a common chemotherapy drug), but have the potential to work in cells that are resistant to paclitaxel. Ixabepilone has caused tumors to shrink or stop growing for a period of time in previous studies
More Information:
Internal Protocol Documents (requires Siteman administrative database password)